Equities research analysts predict that AngioDynamics, Inc. (NASDAQ:ANGO) will report $67.61 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for AngioDynamics’ earnings, with the highest sales estimate coming in at $67.92 million and the lowest estimate coming in at $67.30 million. AngioDynamics posted sales of $85.34 million in the same quarter last year, which suggests a negative year over year growth rate of 20.8%. The business is scheduled to announce its next quarterly earnings results on Thursday, September 26th.
According to Zacks, analysts expect that AngioDynamics will report full year sales of $282.72 million for the current year, with estimates ranging from $282.64 million to $282.80 million. For the next fiscal year, analysts expect that the firm will report sales of $302.05 million, with estimates ranging from $301.20 million to $302.90 million. Zacks’ sales calculations are an average based on a survey of research firms that cover AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.01). The firm had revenue of $96.30 million during the quarter, compared to the consensus estimate of $92.34 million. AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 EPS.
ANGO traded up $0.22 during trading on Tuesday, reaching $18.97. The stock had a trading volume of 96,700 shares, compared to its average volume of 223,076. The stock has a market cap of $698.94 million, a PE ratio of 22.86 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.75 and a current ratio of 4.30. AngioDynamics has a one year low of $18.11 and a one year high of $25.48. The business has a 50-day moving average of $20.46 and a 200-day moving average of $20.95.
In other AngioDynamics news, Director Kevin J. Gould sold 13,650 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $21.45, for a total transaction of $292,792.50. Following the completion of the sale, the director now directly owns 61,774 shares in the company, valued at $1,325,052.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.80% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Financial Gravity Wealth Inc. purchased a new stake in AngioDynamics during the second quarter valued at about $33,000. Nisa Investment Advisors LLC boosted its holdings in shares of AngioDynamics by 100.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 1,100 shares during the period. Advisor Group Inc. boosted its holdings in shares of AngioDynamics by 21.4% during the fourth quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 601 shares during the period. Bank of Montreal Can boosted its holdings in shares of AngioDynamics by 78.7% during the second quarter. Bank of Montreal Can now owns 6,981 shares of the medical instruments supplier’s stock worth $138,000 after purchasing an additional 3,075 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of AngioDynamics by 50.5% during the second quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,029 shares of the medical instruments supplier’s stock worth $178,000 after purchasing an additional 3,029 shares during the period. Institutional investors and hedge funds own 98.37% of the company’s stock.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Story: Convertible Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.